HK1039119A1 - Dihydropyrimidines. - Google Patents

Dihydropyrimidines.

Info

Publication number
HK1039119A1
HK1039119A1 HK02100473A HK02100473A HK1039119A1 HK 1039119 A1 HK1039119 A1 HK 1039119A1 HK 02100473 A HK02100473 A HK 02100473A HK 02100473 A HK02100473 A HK 02100473A HK 1039119 A1 HK1039119 A1 HK 1039119A1
Authority
HK
Hong Kong
Prior art keywords
dihydropyrimidines
Prior art date
Application number
HK02100473A
Other languages
English (en)
Inventor
Jurgen Stoltefuss
Siegfried Goldmann
Thomas Kramer
Karl-Heinz Schlemmer
Ulrich Niewohner
Arnold Paessens
Erwin Graef
Stefan Lottmann
Kark Deres
Olaf Weber
Jorn Stolting
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of HK1039119A1 publication Critical patent/HK1039119A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
HK02100473A 1998-04-18 2002-01-21 Dihydropyrimidines. HK1039119A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19817264A DE19817264A1 (de) 1998-04-18 1998-04-18 Neue Dihydropyrimidine
PCT/EP1999/002344 WO1999054326A1 (de) 1998-04-18 1999-04-07 Dihydropyrimidine

Publications (1)

Publication Number Publication Date
HK1039119A1 true HK1039119A1 (en) 2002-04-12

Family

ID=7864972

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02100473A HK1039119A1 (en) 1998-04-18 2002-01-21 Dihydropyrimidines.

Country Status (37)

Country Link
US (3) US6696451B1 (id)
EP (1) EP1080086B1 (id)
JP (2) JP4590097B2 (id)
KR (1) KR100636771B1 (id)
CN (1) CN1159311C (id)
AR (1) AR018187A1 (id)
AT (1) ATE223401T1 (id)
AU (1) AU740318B2 (id)
BG (1) BG64649B1 (id)
BR (2) BR9909730B1 (id)
CA (1) CA2328780C (id)
CO (1) CO5021127A1 (id)
CU (1) CU23049A3 (id)
CZ (1) CZ293482B6 (id)
DE (2) DE19817264A1 (id)
DK (1) DK1080086T3 (id)
ES (1) ES2183548T3 (id)
GT (1) GT199900056A (id)
HK (1) HK1039119A1 (id)
HU (1) HUP0102372A3 (id)
ID (1) ID27263A (id)
IL (2) IL138584A0 (id)
MY (1) MY126527A (id)
NO (2) NO321985B1 (id)
NZ (1) NZ507569A (id)
PE (1) PE20000427A1 (id)
PL (1) PL193898B1 (id)
PT (1) PT1080086E (id)
RU (1) RU2245881C9 (id)
SI (1) SI1080086T1 (id)
SK (1) SK286407B6 (id)
SV (1) SV1999000047A (id)
TR (1) TR200003011T2 (id)
TW (1) TW548274B (id)
UA (1) UA63998C2 (id)
WO (1) WO1999054326A1 (id)
ZA (1) ZA200005136B (id)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4289100A (en) * 1999-03-25 2000-10-16 Bayer Aktiengesellschaft Dihydropyrimidines and their use in the treatment of hepatitis
EP1193259A4 (en) 1999-06-23 2003-01-29 Ajinomoto Kk dihydropyrimidine
WO2001045712A1 (de) * 1999-12-22 2001-06-28 Bayer Aktiengesellschaft Arzneimittelkombinationen gegen virale erkrankungen
DE10012823A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013125A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013126A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10125131A1 (de) 2001-05-23 2002-12-05 Bayer Ag Verfahren zur Spaltung des Methyl 4-(2-chlor-4-fluorphenyl)-2-(3,5-difluor-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrmidincarboxylat-Racemats
US20040092735A1 (en) * 2002-11-08 2004-05-13 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of cefuroxime sodium
CN101104617B (zh) * 2006-07-10 2010-06-23 北京摩力克科技有限公司 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
CN101104604B (zh) 2006-07-10 2011-03-02 北京摩力克科技有限公司 光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
RU2452733C2 (ru) * 2007-04-27 2012-06-10 Пэдью Фарма Л.П. Антагонисты trpv1 и их применение
KR101173892B1 (ko) * 2007-06-18 2012-08-16 선샤인 레이크 파르마 컴퍼니 리미티드 브로모-페닐 치환된 티아졸릴 디하이드로피리미딘
BRPI0815562A2 (pt) 2007-07-12 2015-02-18 Novartis Ag Soluções farmacêuticas orais contendo telbivudina.
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
HUE034919T2 (en) * 2012-08-24 2018-03-28 Sunshine Lake Pharma Co Ltd 2,4,5,6-substituted 3,6-dihydropyrimidine derivatives such as hepatitis B virus (HBV) polymerase inhibitors, for example, for the treatment of chronic hepatitis
WO2014037480A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN103664899B (zh) * 2012-09-11 2017-06-16 广东东阳光药业有限公司 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
JP2016502519A (ja) * 2012-11-09 2016-01-28 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション Hbv集合エフェクターの代替的使用
CN110960776B (zh) 2013-03-15 2022-10-04 费雪派克医疗保健有限公司 用于医疗回路的组件
TW201609652A (zh) * 2013-11-12 2016-03-16 陶氏農業科學公司 用於氟化化合物之過程(三)
WO2015074546A1 (en) 2013-11-19 2015-05-28 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
RU2688193C1 (ru) 2013-11-27 2019-05-21 Саншайн Лейк Фарма Ко., Лтд. Процессы приготовления производных дигидропиримидина и их промежуточных соединений
MY196243A (en) 2014-03-28 2023-03-24 Sunshine Lake Pharma Co Ltd Dihydropyrimidine Compounds and Their Application In Pharmaceuticals
KR102428878B1 (ko) * 2014-05-30 2022-08-04 치루 파머수티컬 컴퍼니 리미티드 Hbv억제제인 디히드로피리미도 축합환 유도체
CN105153164B (zh) * 2014-05-30 2018-10-30 齐鲁制药有限公司 作为hbv抑制剂的二氢嘧啶并环衍生物
CN105859709B (zh) 2015-02-07 2018-12-04 广东东阳光药业有限公司 二氢嘧啶衍生物的复合物及其在药物中的应用
AU2018291688B2 (en) * 2017-06-27 2022-02-03 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections
US10759774B2 (en) 2017-09-28 2020-09-01 The Curators Of The University Of Missouri Inhibitors of hepatitis B virus targeting capsid assembly
US11236087B2 (en) 2017-11-02 2022-02-01 Aicuris Gmbh & Co. Kg Highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV)
US11267825B2 (en) 2017-11-02 2022-03-08 Aicuris Gmbh & Co. Kg Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV)
CA3097784A1 (en) * 2018-05-08 2019-11-14 Janssen Sciences Ireland Unlimited Company Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
AR117189A1 (es) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
AR116946A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
UY38435A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
AR117188A1 (es) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
WO2020089460A1 (en) * 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv)
UY38436A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
JP2022511819A (ja) 2018-12-20 2022-02-01 ヤンセン ファーマシューティカ エヌ.ベー. ヘテロアリールジヒドロピリミジン誘導体及びb型肝炎感染症を治療する方法
AU2020267015A1 (en) 2019-04-30 2021-12-23 Aicuris Gmbh & Co. Kg Novel indole-2-carboxamides active against the hepatitis B virus (HBV)
JP2022531199A (ja) 2019-04-30 2022-07-06 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト B型肝炎ウイルス(hbv)に対し活性な新規のフェニル及びピリジル尿素
SG11202111493WA (en) 2019-04-30 2021-11-29 Aicuris Gmbh & Co Kg Novel oxalyl piperazines active against the hepatitis b virus (hbv)
US20220227789A1 (en) 2019-04-30 2022-07-21 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
WO2020255016A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH550189A (de) 1971-01-08 1974-06-14 Ciba Geigy Ag Verfahren zur herstellung von neuen dibenzo (b,f) thiepincarbonsaeuren.
CH569043A5 (id) 1973-01-23 1975-11-14 Ciba Geigy Ag
US4371537A (en) * 1981-08-13 1983-02-01 The Dow Chemical Company Sulfur-substituted phenoxypyridines having antiviral activity
DE3234684A1 (de) * 1982-09-18 1984-03-22 Bayer Ag, 5090 Leverkusen Neue dihydropyrimidine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
JPS60185764A (ja) 1984-03-05 1985-09-21 Wako Pure Chem Ind Ltd ピリジン誘導体の新規な製造法
US4698340A (en) * 1984-07-19 1987-10-06 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives, processes for preparation thereof and composition containing the same
US4727073A (en) 1984-10-01 1988-02-23 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives and composition of the same
GB8906168D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
CN1237166A (zh) 1996-11-12 1999-12-01 诺瓦提斯公司 可用作除草剂的吡唑衍生物
SE9702564D0 (sv) * 1997-07-02 1997-07-02 Astra Ab New compounds

Also Published As

Publication number Publication date
BR9909730A (pt) 2000-12-19
BRPI9917862B8 (pt) 2021-05-25
DE59902573D1 (en) 2002-10-10
HUP0102372A2 (hu) 2001-12-28
IL138584A (en) 2006-09-05
EP1080086A1 (de) 2001-03-07
CA2328780C (en) 2008-09-23
TR200003011T2 (tr) 2001-01-22
AU3813399A (en) 1999-11-08
AU740318B2 (en) 2001-11-01
PE20000427A1 (es) 2000-06-25
SV1999000047A (es) 2000-06-23
ID27263A (id) 2001-03-22
KR100636771B1 (ko) 2006-10-23
JP4590097B2 (ja) 2010-12-01
BRPI9917862A2 (id) 2010-12-07
WO1999054326A1 (de) 1999-10-28
NO20005215L (no) 2000-12-13
BG64649B1 (bg) 2005-10-31
CA2328780A1 (en) 1999-10-28
TW548274B (en) 2003-08-21
BR9909730B1 (pt) 2012-09-04
BRPI9917862B1 (pt) 2013-05-07
ATE223401T1 (de) 2002-09-15
CN1159311C (zh) 2004-07-28
RU2245881C9 (ru) 2006-02-10
EP1080086B1 (de) 2002-09-04
BG104812A (en) 2001-06-29
JP2002512243A (ja) 2002-04-23
GT199900056A (es) 2000-10-07
CN1305471A (zh) 2001-07-25
SI1080086T1 (en) 2003-02-28
CZ20003871A3 (cs) 2001-01-17
NO20045259L (no) 2000-12-13
US20040167135A1 (en) 2004-08-26
IL138584A0 (en) 2001-10-31
RU2245881C2 (ru) 2005-02-10
PL343481A1 (en) 2001-08-27
KR20010042788A (ko) 2001-05-25
MY126527A (en) 2006-10-31
DE19817264A1 (de) 1999-10-21
US7514565B2 (en) 2009-04-07
NZ507569A (en) 2002-04-26
WO1999054326A8 (de) 1999-12-29
HUP0102372A3 (en) 2003-01-28
AR018187A1 (es) 2001-10-31
JP2010241837A (ja) 2010-10-28
JP5237332B2 (ja) 2013-07-17
PL193898B1 (pl) 2007-03-30
DK1080086T3 (da) 2002-12-23
NO329020B1 (no) 2010-07-26
SK286407B6 (sk) 2008-09-05
US6696451B1 (en) 2004-02-24
NO321985B1 (no) 2006-07-31
CU23049A3 (es) 2005-06-24
CZ293482B6 (cs) 2004-05-12
ES2183548T3 (es) 2003-03-16
PT1080086E (pt) 2002-12-31
CO5021127A1 (es) 2001-03-27
NO20005215D0 (no) 2000-10-17
US20070117812A1 (en) 2007-05-24
UA63998C2 (uk) 2004-02-16
SK15652000A3 (sk) 2001-04-09
ZA200005136B (en) 2001-03-02

Similar Documents

Publication Publication Date Title
HK1039119A1 (en) Dihydropyrimidines.
HK1037188A1 (en) Novel 2-heterocyclically substituted dihydropyrimidines.
ZA996185B (en) Sulfanylsilanes.
MXPA01013362A (es) Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
ZA200200477B (en) 2-pyrazolin-5-ones.
HK1030387A1 (en) Shank fitting structure.
HK1054384A1 (en) 4-Pyrimidinyl-n-acyl-l-phenylalanines.
HK1016976A1 (en) Resorcinyl-triazine.
ZA991272B (en) Novel thiobenzamides.
HK1053470A1 (en) 4-Pyridinyln-acyl-l-phenylalanines.
ZA981926B (en) Detergent--package combination.
ZA992322B (en) Phosphodiesterase iv-inhibiting diazepinoindoles.
ZA987055B (en) Substituted 4-benzoylpyrazoles.
ZA992443B (en) Hydroxy-methyl-hexanones.
ZA987058B (en) Substituted 4-benzoylpyrazoles.
ZA995325B (en) Methylcyclotetradec-5-en-1-ones.
ZA993123B (en) Trisresorcinyltriazines.
HK1017834A1 (en) Bodyshaper.
HK1021879A1 (en) Carrying case.
ZA996913B (en) Tetrahydronaphthalenes.
ZA983705B (en) Pregnan-3-ol-20-ones.
ZA987B (en) Substituted 4-benzoylpyrazoles.
HK1028588A1 (en) Case.
ZA981309B (en) 4-aminoalkoxy-1H-benzoimidazoles.
ZA983795B (en) Substituted 4-benzoyl-pyrazoles.

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20190406